Study of heart amyloid risk in people with TTR gene variants
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 30–80 years old, and either have a harmful TTR gene change (like V122I) or are a matched comparison person without it
- If you do NOT have heart failure symptoms: you must not have been hospitalized for heart failure in the last 12 months and your heart-failure blood tests must not be high
- If you DO have heart failure symptoms: you must have a confirmed or strongly suspected diagnosis of TTR-related heart amyloidosis (using approved test results or scans)
- You must be able to sign consent and follow study instructions
- You cannot have other known reasons for heart muscle weakness, or a past history of light-chain heart amyloidosis
- Certain heart events and treatments can rule you out (for example, past heart transplant, and for symptomatic cases, recent tafamidis/acoramidis or TTR-silencer medicines)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tiny particles called extracellular vesicles in the blood of people with a specific type of heart amyloidosis. It aims to find better ways to track the disease and predict outcomes.
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
This study is observing people with amyloidosis or those who carry a specific gene mutation (transthyretin) to learn more about the condition. It does not test any new treatment, but may help researchers understand how the disease affects people.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
This study uses PET/CT scans to look at the heart in people who carry a genetic change (TTR mutation) that can cause a heart condition called amyloidosis, and compares them with people who have symptoms and healthy controls. It may help doctors better understand and detect the disease earlier.
Hear when a new Amyloidosis, Hereditary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.